Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J J van Veen

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Acta Haematologica|April 25, 2008
Altitude and coagulation activation: does going high provoke thrombosis?J J van Veen, M Makris
Journal of Thrombosis and Haemostasis : JTH|April 22, 2005
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity--a rebuttalM Makris, J J Van Veen
Anaesthesia|December 3, 2014
Management of peri-operative anti-thrombotic therapyJ J van Veen, M Makris
Journal of Thrombosis and Haemostasis : JTH|October 25, 2011
Reduced cardiovascular mortality in hemophilia despite normal atherosclerotic loadMike Makris, J J Van Veen
International Journal of Laboratory Hematology|May 1, 2018
Argatroban is stable in citrated whole blood for 24 hoursS Guy, S Kitchen, J J Van Veen
International Journal of Clinical Practice|August 21, 2010
Recombinant factor VIIa for unlicensed indications--a definite No or a cautious Maybe in selected patients?Y Sorour, J J Van Veen, M Makris
British Journal of Haematology|June 20, 2008
Thrombin generation testing in routine clinical practice: are we there yet?J J van Veen, A Gatt, M Makris
British Journal of Anaesthesia|December 15, 2010
Routine preoperative coagulation tests: an outdated practice?J J van Veen, D R Spahn, M Makris
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 20, 2008
Paracetamol/acetaminophen usage in haemophilia: more caution needed?J J van Veen, D C Gleeson, M Makris
International Journal of Laboratory Hematology|August 26, 2015
Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatrobanS Guy, S Kitchen, R Maclean, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Acta Haematologica|April 25, 2008
Altitude and coagulation activation: does going high provoke thrombosis?J J van Veen, M Makris
Journal of Thrombosis and Haemostasis : JTH|April 22, 2005
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity--a rebuttalM Makris, J J Van Veen
Anaesthesia|December 3, 2014
Management of peri-operative anti-thrombotic therapyJ J van Veen, M Makris
Journal of Thrombosis and Haemostasis : JTH|October 25, 2011
Reduced cardiovascular mortality in hemophilia despite normal atherosclerotic loadMike Makris, J J Van Veen
International Journal of Laboratory Hematology|May 1, 2018
Argatroban is stable in citrated whole blood for 24 hoursS Guy, S Kitchen, J J Van Veen
International Journal of Clinical Practice|August 21, 2010
Recombinant factor VIIa for unlicensed indications--a definite No or a cautious Maybe in selected patients?Y Sorour, J J Van Veen, M Makris
British Journal of Haematology|June 20, 2008
Thrombin generation testing in routine clinical practice: are we there yet?J J van Veen, A Gatt, M Makris
British Journal of Anaesthesia|December 15, 2010
Routine preoperative coagulation tests: an outdated practice?J J van Veen, D R Spahn, M Makris
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 20, 2008
Paracetamol/acetaminophen usage in haemophilia: more caution needed?J J van Veen, D C Gleeson, M Makris
International Journal of Laboratory Hematology|August 26, 2015
Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatrobanS Guy, S Kitchen, R Maclean, et al.
Pageof 2